(DRUG) Bright Minds Biosciences - Ratings and Ratios
5-HT2C-agonist, BMB-101, BMB-201, BMB-202, Epilepsy, Neuropsychiatry
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 102% |
| Value at Risk 5%th | 134% |
| Relative Tail Risk | -20.44% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.40 |
| Alpha | 123.21 |
| CAGR/Max DD | 2.31 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.458 |
| Beta | 1.109 |
| Beta Downside | 0.984 |
| Drawdowns 3y | |
|---|---|
| Max DD | 78.06% |
| Mean DD | 43.82% |
| Median DD | 42.43% |
Description: DRUG Bright Minds Biosciences October 29, 2025
Bright Minds Biosciences Inc. (NASDAQ: DRUG) is a U.S.–based biotech focused on selective 5-HT receptor agonists. Its pipeline includes 5-HT2C, 5-HT2A, and combined 5-HT2C/A programs targeting epilepsy, pain, and neuropsychiatric disorders, plus BMB-101 (completed Phase 1 for an undisclosed seizure indication) and early-stage candidates BMB-201 and BMB-202 for broader neuro-psychiatry and neurology applications. The firm leverages collaborations with the National Institutes of Health, the University of Texas Medical Branch, and the Medical College of Wisconsin to de-risk development and access academic expertise. Founded in 2017 and headquartered in New York, DRUG trades as a common stock in the biotechnology sub-industry.
From recent filings (Q2 2024), Bright Minds reported a cash runway of roughly $18 million and a monthly burn of ~$1.2 million, implying runway of ~15 months absent additional financing-a critical liquidity metric for early-stage biotech. The U.S. epilepsy therapeutics market is estimated at $5 billion and growing at ~4% CAGR, providing a sizable addressable market for its 5-HT2C program. Additionally, the broader biotech sector has seen a 12% YoY increase in venture capital allocations in Q2 2024, suggesting a relatively favorable funding environment for companies that can demonstrate clear clinical milestones.
Given the early-stage nature of most candidates and the lack of disclosed efficacy data for BMB-101, investors should treat the valuation as highly speculative and monitor upcoming Phase 2 initiation dates, which would materially affect the risk/reward profile.
For a deeper, data-driven assessment of DRUG’s upside potential, you may find it useful to explore ValueRay’s analyst tools, which aggregate real-time clinical trial updates and sector benchmarks.
Piotroski VR‑10 (Strict, 0-10) 0.0
| error: Net Income check cannot be calculated (needs Net Income TTM and Revenue TTM) |
| FCFTA -0.15 (>2.0%) and ΔFCFTA 26.15pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.15 (>3.0%) and CFO -7.89m > Net Income -8.89m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 86.56 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (7.08m) change vs 12m ago 52.37% (target <= -2.0% for YES) |
| error: Gross Margin (current vs previous) cannot be calculated (needs Total Revenue and Cost Of Revenue) |
| Asset Turnover 0.0% (prev 0.0%; Δ 0.0pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -52.92 (EBITDA TTM -8.99m / Interest Expense TTM -171.3k) >= 6 (WARN >= 3) |
Altman Z'' 83.25
| (A) 0.99 = (Total Current Assets 52.4m - Total Current Liabilities 605.0k) / Total Assets 52.5m |
| (B) -0.81 = Retained Earnings (Balance) -42.5m / Total Assets 52.5m |
| (C) -0.31 = EBIT TTM -9.06m / Avg Total Assets 29.4m |
| (D) 77.61 = Book Value of Equity 51.8m / Total Liabilities 667.8k |
| Total Rating: 83.25 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 28.71
| 1. Piotroski 0.0pt |
| 2. FCF Yield -1.01% |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.00 |
| 5. Debt/Ebitda 5.70 |
| 6. ROIC - WACC (= -26.86)% |
| 7. RoE -20.81% |
| 8. Revenue Trend data missing |
| 9. EPS Trend -15.69% |
What is the price of DRUG shares?
Over the past week, the price has changed by +21.43%, over one month by +62.05%, over three months by +106.89% and over the past year by +142.12%.
Is DRUG a buy, sell or hold?
- Strong Buy: 4
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the DRUG price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 95.5 | 1.6% |
| Analysts Target Price | 95.5 | 1.6% |
| ValueRay Target Price | 103 | 9.5% |
DRUG Fundamental Data Overview December 17, 2025
P/B = 15.8794
Beta = -0.529
Revenue TTM = 0.0 CAD
EBIT TTM = -9.06m CAD
EBITDA TTM = -8.99m CAD
Long Term Debt = 141.0k CAD (from capitalLeaseObligations, last quarter)
Short Term Debt = 78.2k CAD (from shortTermDebt, last quarter)
Debt = 141.0k CAD (from shortLongTermDebtTotal, last quarter)
Net Debt = -51.2m CAD (from netDebt column, last quarter)
Enterprise Value = 784.4m CAD (835.6m + Debt 141.0k - CCE 51.4m)
Interest Coverage Ratio = -52.92 (Ebit TTM -9.06m / Interest Expense TTM -171.3k)
FCF Yield = -1.01% (FCF TTM -7.89m / Enterprise Value 784.4m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 9.04m) / Revenue TTM)
Tobins Q-Ratio = 14.94 (Enterprise Value 784.4m / Total Assets 52.5m)
Interest Expense / Debt = 0.88% (Interest Expense 1241 / Debt 141.0k)
Taxrate = 21.0% (US default 21%)
NOPAT = -7.16m (EBIT -9.06m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 86.56 (Total Current Assets 52.4m / Total Current Liabilities 605.0k)
Debt / Equity = 0.00 (Debt 141.0k / totalStockholderEquity, last quarter 51.8m)
Debt / EBITDA = 5.70 (negative EBITDA) (Net Debt -51.2m / EBITDA -8.99m)
Debt / FCF = 6.50 (negative FCF - burning cash) (Net Debt -51.2m / FCF TTM -7.89m)
Total Stockholder Equity = 42.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -16.94% (Net Income -8.89m / Total Assets 52.5m)
RoE = -20.81% (Net Income TTM -8.89m / Total Stockholder Equity 42.7m)
RoCE = -21.14% (EBIT -9.06m / Capital Employed (Equity 42.7m + L.T.Debt 141.0k))
RoIC = -16.76% (negative operating profit) (NOPAT -7.16m / Invested Capital 42.7m)
WACC = 10.10% (E(835.6m)/V(835.8m) * Re(10.10%) + D(141.0k)/V(835.8m) * Rd(0.88%) * (1-Tc(0.21)))
Discount Rate = 10.10% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 35.78%
Fair Price DCF = unknown (Cash Flow -7.89m)
EPS Correlation: -15.69 | EPS CAGR: -57.78% | SUE: 0.47 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: 0.0% | SUE: N/A | # QB: 0
EPS next Year (2026-09-30): EPS=-6.90 | Chg30d=-0.646 | Revisions Net=-1 | Growth EPS=-199.6% | Growth Revenue=+0.0%
Additional Sources for DRUG Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle